Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …

As prostate cancer (PCa) progresses to the lethal castration resistant and metastatic form,
genetic and epigenetic adaptation, clonal selection, and evolution of the tumor …

In the past five years, multiple structurally and functionally distinct androgen receptor (AR)
splice variants have been decoded and characterized. The mature transcripts for the …

Androgen/androgen receptor (AR) signaling plays pivotal roles in the prostate development
and homeostasis as well as in the progression of prostate cancer (PCa). Androgen …

Ursolic acid (UA), a pentacyclic triterpenoid, is known to exert antitumor activity in breast,
lung, liver and colon cancers. Nonetheless, the underlying mechanism of ursolic acid in …

Prostate cancer (PC) is the most prevalent male urogenital cancer worldwide. PC patients
presenting an advanced or metastatic cancer succumb to the disease, even after therapeutic …

Background: Sorafenib is a potent inhibitor against Raf kinase and several receptor tyrosine
kinases that has been approved for the clinical treatment of advanced renal and liver cancer …

Although sorafenib is currently used as a standard treatment for advanced hepatocellular
carcinoma, low response rate, transient and limited efficacy, primary and acquired …

Abstract Prostate Cancer (PCa) is an important age-related disease being the most common
cancer malignancy and the second leading cause of cancer mortality in men in Western …

Sorafenib (SRF) is a multi-kinase inhibitor that has been shown to have antitumor activity
against several types of cancers, but the effect of SRF on EBV-transformed B cells is …